Status:
UNKNOWN
A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Idiopathic Retroperitoneal Fibrosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This is a prospective study to investigate the treatment response of Tocilizumab on patients with idiopathic retroperitoneal fibrosis（IRPF）. Methods: All the patients fulfilling diagnostic criteria o...
Eligibility Criteria
Inclusion
- age 18-75 diagnosed as IRPF: The diagnosis of idiopathic retroperitoneal fibrosis is based on the following aspects :(1) the swelling of retroperitoneal tissue , which seems neoplastic; (2) A large number of lymphocytes proliferated and infiltrated in the affected tissues and organs, and tissues showed inflammation, fibrosis and sclerosis, in which IgG4-positive cells accounted for less than 50% of plasma cells; (3) Increased inflammatory markers, such as ESR and CRP; (4) Good response to glucocorticoid therapy.
Exclusion
- malignancy retroperitoneal fibrosis secondary to other diseases or drug treatment or abdominal surgeries.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 10 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04762784
Start Date
July 1 2020
End Date
February 10 2023
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100032